Therapeutic Advances in Musculoskeletal Disease

Papers
(The H4-Index of Therapeutic Advances in Musculoskeletal Disease is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Actigraphy-derived physical activity levels and circadian rhythm parameters in patients with psoriatic arthritis: relationship with disease activity, mood, age and BMI141
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment80
Is there wastage in the research resources for ankylosing spondylitis? An analysis of clinical trial discontinuation and nonpublication outcome44
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis41
Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study37
The socioeconomic status of patients with ankylosing spondylitis and its association with the burden of the disease and permanent disability: a cross-sectional cluster analysis33
Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients31
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review31
Comparable long-term retention rates and effects on bone mineral density of denosumab treatment in patients with osteoporosis with or without autoimmune inflammatory rheumatic diseases: real-life data30
Cardio-rheumatology: integrated care and the opportunities for personalized medicine29
Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs)29
Similarities and differences: disentangling the intersection between axial psoriatic arthritis and axial spondyloarthritis29
Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients28
Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials27
Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry26
Reduced bone mineral density in patients with idiopathic inflammatory myopathies: a case-control study26
Calcineurin inhibitors in systemic sclerosis – a systematic literature review25
Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versus weak opioids25
The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs24
Health disparities in rheumatoid arthritis23
Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors23
The association between gout flares and monosodium urate burden assessed using musculoskeletal ultrasound in patients with gout21
Bone fragility: conceptual framework, therapeutic implications, and COVID-19-related issues21
0.16187286376953